364 related articles for article (PubMed ID: 12783693)
1. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
3. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
4. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
5. [Treatment and prognostic factors of epithelial ovarian cancer].
Wei L; Qian H; Li W
Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):476-9. PubMed ID: 9639741
[TBL] [Abstract][Full Text] [Related]
6. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?
Benito V; Lubrano A; Arencibia O; Medina N; Álvarez Eva E; Andújar M; Falcón Juan M; Falcón O
Eur J Obstet Gynecol Reprod Biol; 2010 Dec; 153(2):188-92. PubMed ID: 20728981
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
[TBL] [Abstract][Full Text] [Related]
8. [The clinical and pathological characteristics of epithelial ovarian carcinoma in patients with age under 40].
Wen H; Sun W; Guo Y
Zhonghua Fu Chan Ke Za Zhi; 1997 Sep; 32(9):548-51. PubMed ID: 9639757
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of long-term prognostic factors of epithelial ovarian cancer].
Li MD; Li YJ; Huang YW; Huang H
Ai Zheng; 2004 Nov; 23(11):1306-10. PubMed ID: 15522179
[TBL] [Abstract][Full Text] [Related]
10. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
12. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
14. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
17. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological characteristics of hereditary ovarian cancer syndrome].
Zhong Y; Sheng XG; Ma ZF; Ma YB; Liu NF; Chen YT; Gao R; Wang YY; Sun L
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):676-80. PubMed ID: 20079180
[TBL] [Abstract][Full Text] [Related]
19. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.
Leary A; Petrella MC; Pautier P; Duvillard P; Uzan C; Tazi Y; Ledoux F; Gouy S; Morice P; Lhommé C
Gynecol Oncol; 2014 Jan; 132(1):23-7. PubMed ID: 24219980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
